|
|
1.
|
Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score >= 50. MedStar authors:
Year: 2021
Citation: - Journal of Clinical Oncology. 39(21):2339-2349, 2021 07 20.
Institution: - MedStar Franklin Square Medical Center
Medline publication type:
All authors: - Brahmer JR, Csoszi T, Cuffe S, Fulop A, Gottfried M, Hotta K, Hui R, Jensen E, Leal TA, O'Brien M, Peled N, Pietanza MC, Rao S, Reck M, Riess JW, Robinson AG, Rodriguez-Abreu D, Tafreshi A, Zhao B
|
|
|
2.
|
Safety and Activity of Immune Checkpoint Inhibitors in People Living With HIV and Cancer: A Real-World Report From the Cancer Therapy Using Checkpoint Inhibitors in People Living With HIV-International (CATCH-IT) Consortium. MedStar authors:
Year: 2023
Citation: - Journal of Clinical Oncology. 41(21):3712-3723, 2023 07 20.
Institution: - MedStar Washington Hospital Center
Department: - Internal Medicine Residency
Medline publication type:
All authors: - Abdallah W, Abdel-Wahab N, Aboubakar Nana F, Abu Ghazal B, Addeo A, Adib E, Al-Hader A, Arora A, Baden LR, Baena J, Bahary N, Baiocchi RA, Bakalov V, Bankapur A, Barletta G, Bersanelli M, Bower M, Chiao EY, Choueiri TK, Cortellini A, Dalla Pria A, Diab A, Dima D, Dittus C, Dizman N, Dobbs RW, Drakaki A, Drolen C, El Zarif T, El-Am E, Emu B, Falohun A, Fitzgerald BG, Florou V, Freeman D, Funchain P, Genova C, Hall E, Haykal T, Huang J, Idossa D, Johnson DB, Kim C, Kozaily E, Lamberti G, Lechner MG, Li M, Long GV, Lopetegui-Lia N, Lorentsen M, Lurain K, Mangla A, Marron TU, McKay RR, Menzies AM, Mittra A, Morse MA, Mouhieddine TH, Naqash AR, Nassar AH, Nebhan CA, Nonato T, Owen DH, Pinato DJ, Puri S, Queirolo P, Rajkumar A, Ramaswami R, Reed A, Reid EG, Rubinstein PG, Saeed A, Saleem R, Saponara M, Shah NJ, Shah V, Sharon E, Singh P, Sonpavde GP, Woodford R, Xie W
|
|
|
3.
|
Health-related quality-of-life results for pembrolizumab versus chemotherapy in advanced, PD-L1-positive NSCLC (KEYNOTE-024): a multicentre, international, randomised, open-label phase 3 trial. MedStar authors:
Year: 2017
Citation: - Lancet Oncology. 18(12):1600-1609, 2017 Dec
Institution: - MedStar Franklin Square Hospital
Medline publication type:
All authors: - Brahmer JR, Csoszi T, Cuffe S, Deitz AC, Fulop A, Gottfried M, Hotta K, Hui R, Lubiniecki GM, O'Brien M, Peled N, Rangwala R, Rao S, Reck M, Robinson AG, Rodriguez-Abreu D, Tafreshi A, Zhang J
|
|
|
4.
|
Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater. MedStar authors:
Year: 2019
Citation: - Journal of Clinical Oncology. 37(7):537-546, 2019 03 01.
Institution: - Medstar Franklin Square Medical Center
Medline publication type:
All authors: - Brahmer JR, Csoszi T, Cuffe S, Fulop A, Gottfried M, Hotta K, Hui R, O'Brien M, Peled N, Pietanza MC, Rao S, Reck M, Riccio A, Robinson AG, Rodriguez-Abreu D, Tafreshi A, Vandormael K, Yang J
|
